U.S. markets open in 7 hours 43 minutes
  • S&P Futures

    3,825.00
    -9.00 (-0.23%)
     
  • Dow Futures

    30,858.00
    -78.00 (-0.25%)
     
  • Nasdaq Futures

    11,788.25
    -20.25 (-0.17%)
     
  • Russell 2000 Futures

    1,734.60
    -7.10 (-0.41%)
     
  • Crude Oil

    99.70
    +0.20 (+0.20%)
     
  • Gold

    1,763.90
    0.00 (0.00%)
     
  • Silver

    18.95
    -0.17 (-0.87%)
     
  • EUR/USD

    1.0250
    -0.0020 (-0.19%)
     
  • 10-Yr Bond

    2.8090
    0.0000 (0.00%)
     
  • Vix

    27.54
    +0.01 (+0.04%)
     
  • GBP/USD

    1.1931
    -0.0020 (-0.17%)
     
  • USD/JPY

    135.2690
    -0.5730 (-0.42%)
     
  • BTC-USD

    20,021.19
    -335.92 (-1.65%)
     
  • CMC Crypto 200

    433.64
    -6.39 (-1.45%)
     
  • FTSE 100

    7,025.47
    -207.18 (-2.86%)
     
  • Nikkei 225

    26,145.75
    -277.72 (-1.05%)
     

Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Leerink 2022 Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LEXINGTON, Mass., February 10, 2022--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 2022 Global Healthcare Conference.

Dr. Brady’s conversation with Marc Goodman, Senior Research Analyst at SVB Leerink, will be available on demand beginning at 9:20 a.m. ET Wednesday, February 16, 2022. To view the webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. The event will remain archived on the website for 90 days.

About Aldeyra Therapeutics

Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 proof-of-concept clinical trials in psoriasis, asthma, and COVID-19. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220209005818/en/

Contacts

Corporate:
Joshua Reed
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
jreed@aldeyra.com

Investor & Media:
Scott Solomon
Sharon Merrill Associates, Inc.
Tel: 617-542-5300
ALDX@investorrelations.com